Skip to main content

COVID-19 Topic Center

Hepatitis News

News
By Reuters Staff (Reuters) - Shares of Spring Bank Pharmaceuticals plummeted 26% on Wednesday after the company said it would end the development of an experimental drug to treat chronic hepatitis B virus, following the death of a patient in a mid-stage trial. The drug developer said the "…
News
The US Food and Drug Administration (FDA) has issued a drug safety warning about the use of 3 medications for hepatitis C virus (HCV) among individuals with moderate to severe liver impairment. The warning comes after 63 individuals who received treatment for chronic HCV with glecaprevir/…
News
Researchers recently compared how the use of lipophilic or hydrophilic statins impacted hepatocellular carcinoma (HCC) in patients with viral hepatitis. According to the research team, prior to the study, it was unknown whether statin type influenced HCC incidence or mortality in patients with…
News
Patients with chronic hepatitis C virus (HCV) infection who have a history of hepatocellular carcinoma (HCC) face a higher risk of direct-antiviral agent (DAA) treatment failure, according to a new study published online in the Journal of Viral Hepatitis. For their study, the researchers evaluated…
News
The CDC has warned of outbreaks in multiple states of hepatitis A infection among individuals who use drugs or who are homeless. Over 2500 reports of hepatitis A infection related to person-to-person transmission were reported from January 2017 to April 2018 in multiple states. Risk factors were…
News
After accounting for baseline health status and demographic characteristics, a new population-based study found patients with hepatitis C virus (HCV) infection treated with direct-acting antivirals (DAAs) were at significantly reduced risk of liver cancer compared with no treatment and interferon-…
News
A direct-acting antiviral (DAA) combination of sofosbuvir, velpatasvir, and voxilaprevir is safe and effective for the treatment of patients with hepatitis C virus (HCV) infection who were previously treated with DAAs, according to a recent study. Sofosbuvir/velpatasvir/voxilaprevir is indicated…
News
The rate of hepatitis B (HBV) reactivation was low in patients with resolved HBV who received  disease-modifying antirheumatic drugs (DMARDs) for inflammatory arthritis, according to a systematic review and meta-analysis published online in Arthritis Care & Research (doi: 10.1002/acr.23346).…
News
Some revolutionary drugs capable of curing hepatitis may be associated with some severe adverse events, including liver failure, according to a report released by the Institute for Safe Medication Practices (ISMP), a nonprofit organization in Horsham, PA, that studies drug safety.…
News
By Reuters Staff (Reuters) - The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients. The agency recommended that patients be screened to ensure they are not infected with both kinds of virus…
Back to Top